|
Apr 6
|
Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes
|
|
Apr 3
|
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
|
|
Apr 3
|
Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market
|
|
Mar 31
|
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
|
|
Mar 30
|
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
|
|
Mar 20
|
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
|
|
Mar 12
|
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’
|
|
Mar 10
|
Why Recursion Pharmaceuticals Stock Is Sinking Today
|
|
Feb 24
|
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
|
|
Feb 23
|
Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?
|
|
Feb 21
|
Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)
|
|
Feb 19
|
Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025
|
|
Feb 19
|
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
|
|
Feb 19
|
Recursion CEO launches pre-seed fund in response to NIH cuts
|
|
Feb 18
|
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
|
|
Feb 18
|
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)
|
|
Feb 18
|
Altitude Lab Startups Raise $154M in Capital
|
|
Feb 18
|
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
|
|
Feb 17
|
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week
|
|
Oct 8
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
|